Molecular Insight Announces Updates to Board of Directors
January 27 2010 - 4:01PM
Marketwired
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI), a
biopharmaceutical company discovering and developing targeted
therapeutic and imaging radiopharmaceuticals for use in oncology,
announced that David R. Epstein and Yvonne Greenstreet, M.D., have
resigned from its Board of Directors.
The resignations of Mr. Epstein and Dr. Greenstreet reflect
significantly increased work commitments at their respective
companies. Mr. Epstein recently was promoted to Head of
Pharmaceuticals at Novartis and is relocating to Switzerland. Dr.
Greenstreet serves as Senior Vice President and Chief of Strategy,
Research and Development at GlaxoSmithKline.
"We have greatly appreciated David and Yvonne's guidance during
this pivotal stage of Molecular Insight's development," said Joseph
M. Limber, Chairman of the Board.
Daniel L. Peters, President and CEO, said, "Both of these
industry leaders have played important roles in helping the Company
focus on our pipeline of oncology product candidates and
identifying important areas of unmet medical need in which our
therapeutics are uniquely suited to positively impact patient
lives. We thank them for their efforts and wish them well in future
endeavors."
About Molecular Insight Pharmaceuticals, Inc.
Molecular Insight Pharmaceuticals is a clinical-stage
biopharmaceutical company and pioneer in molecular medicine. The
Company is focused on the discovery and development of targeted
therapeutic and imaging radiopharmaceuticals for use in oncology.
Molecular Insight has five clinical-stage candidates in
development. For further information on Molecular Insight
Pharmaceuticals, please visit www.molecularinsight.com.
Forward-Looking Statements
Statements in this release that are not strictly historical in
nature constitute "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. Such
statements include, but are not limited to, statements about our
product focus, targeted markets and therapeutic impact on patient
lives. Such forward-looking statements involve known and unknown
risks, uncertainties, and other factors that may cause the actual
results of Molecular Insight to be materially different from
historical results or from any results expressed or implied by such
forward-looking statements. These factors include, but are not
limited to, risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product
development programs; difficulties or delays in obtaining
regulatory approval for product candidates; difficulties or delays
in obtaining financing, modifying our existing financing
arrangements and generating the revenue as anticipated; competition
from other pharmaceutical or biotechnology companies; and the
additional risks discussed in filings with the Securities and
Exchange Commission (SEC). The Company's SEC filings are available
through the SEC's Electronic Data Gathering Analysis and Retrieval
system (EDGAR) at http://www.sec.gov/. Press releases for Molecular
Insight Pharmaceuticals, Inc. are available on our website:
http://www.molecularinsight.com/. All forward-looking statements
are qualified in their entirety by this cautionary statement, and
Molecular Insight undertakes no obligation to revise or update this
release to reflect events or circumstances after the date
hereof.
Contact: Investors Chuck Abdalian Chief Financial Officer (617)
871-6618 cabdalian@molecularinsight.com Media Martin A. Reynolds
Manager Corporate Communications (617) 871-6734
mreynolds@molecularinsight.com Susan Pietropaolo BCC Partners (201)
923-2049 spietropaolo@bccpartners.com
Molecular Insight Pharmaceuticals (MM) (NASDAQ:MIPI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Molecular Insight Pharmaceuticals (MM) (NASDAQ:MIPI)
Historical Stock Chart
From Sep 2023 to Sep 2024